MedCore Peptides Contact →
MedCore Multi-Strength Research Profile

Tirzepatide 10 mg & 20 mg

One canonical Tirzepatide entity page for MedCore 10 mg and 20 mg presentations, separating compound identity and authorized-medicine evidence from MedCore product information.

View Presentations ↓Regulatory Context →
MedCore Tirzepatide 10 mg product presentation
MedCore Tirzepatide 20 mg product presentation
ONE ENTITY PAGE2 MedCore strengths10 mg + 20 mg
CompoundTirzepatide
MedCore strengths10 mg / 20 mg
PubChem CID156588324
ClassDual GIP / GLP-1 agonist
Peptide length39 amino acids
Page reviewed2 Sep 2026

What is Tirzepatide?

PubChem lists Tirzepatide as CID 156588324 and describes it as a 39-amino-acid synthetic peptide with dual activity at glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. PubChem reports molecular formula C225H348N48O68 and molecular weight about 4813 g/mol.1

Tirzepatide is also the active substance in authorized prescription medicines. EMA lists Mounjaro with tirzepatide as the active substance, while FDA has approved Zepbound, another specific tirzepatide medicine. These product approvals do not automatically apply to the MedCore research presentations.23

Tirzepatide Regulatory & Evidence Context

A trustworthy page keeps approved-drug evidence attached to named authorized medicines rather than transferring it to an unrelated product carrying the same compound name.

European Medicines Agency

Mounjaro is a specific authorized tirzepatide medicine

EMA identifies tirzepatide as the active substance in Mounjaro and publishes medicine-specific product information and authorized indications for that product.2

Important distinctionThe authorization belongs to Mounjaro as reviewed by regulators. It does not make every tirzepatide-labeled product equivalent or authorized.
U.S. FDA

Zepbound is a specific FDA-approved tirzepatide medicine

FDA announced approval of Zepbound (tirzepatide) in November 2023 and notes tirzepatide was already approved under the Mounjaro trade name for a separate indication.3

PubChem

Standardized Tirzepatide identity

PubChem lists Tirzepatide as CID 156588324, a 39-amino-acid synthetic peptide and dual GIP/GLP-1 receptor agonist.1

Evidence boundary: This page does not use Mounjaro or Zepbound approvals, dosing, indications, safety labeling or clinical outcomes as claims for the MedCore Tirzepatide presentations.

Available MedCore Tirzepatide Presentations

Both strengths share one canonical compound page to avoid duplicating the same compound and regulatory context.

MedCore Tirzepatide 10 mg research presentation
10 mg

MedCore Tirzepatide 10 mg

A distinct MedCore 10 mg Tirzepatide research presentation on the canonical Tirzepatide entity page.

CompoundTirzepatideStrength10 mgPortfolioMetabolic researchWebsite purposeResearch information
MedCore Tirzepatide 20 mg research presentation
20 mg

MedCore Tirzepatide 20 mg

A separate MedCore 20 mg Tirzepatide presentation represented on the same canonical compound page.

CompoundTirzepatideStrength20 mgPortfolioMetabolic researchWebsite purposeResearch information
Variant policy: Strength-specific product identification is preserved, while the common Tirzepatide entity, evidence and references remain on one canonical URL.

Quality & Documentation

Product documentation should describe each MedCore strength without borrowing approval, dosing or clinical claims from Mounjaro or Zepbound.

  • Strength-specific product identification
  • Batch documentation when published
  • Analytical records when verified
  • Regulatory evidence kept product-specific
Explore MedCore Quality →
MC
MEDCORE PEPTIDESTirzepatide profile
Canonical entityTirzepatide
Presentation A10 mg
Presentation B20 mg
Compound sourcePubChem
Regulatory sourcesEMA / FDA
No purity, batch, route or equivalence claim is asserted without MedCore documentation.

COA / Laboratory Documentation

Strength-specific documentation preview for the MedCore Tirzepatide research presentation.

Sample COA / laboratory documentation for MedCore Tirzepatide 10 mg
Tirzepatide 10 mgSample documentation for presentation purposes; not independently verified.
Sample COA / laboratory documentation for MedCore Tirzepatide 20 mg
Tirzepatide 20 mgSample documentation for presentation purposes; not independently verified.
Documentation note

These images are presented as sample product documentation and should not be interpreted as independently verified analytical certification. Product identity, batch data and analytical claims should be checked against original laboratory records.

Related MedCore Research Profiles

Related metabolic entities are connected through descriptive internal links.

Metabolic researchSemaglutideExplore profile →Metabolic researchRetatrutideExplore profile →Peptide researchGHK-CuExplore profile →

Tirzepatide Questions & Answers

Concise answers preserve compound, authorized-medicine and MedCore product boundaries.

Tirzepatide is a 39-amino-acid synthetic peptide with dual GIP and GLP-1 receptor agonist activity. PubChem lists it as CID 156588324.1
Yes. EMA lists Mounjaro and FDA has approved Zepbound, both specific medicines containing tirzepatide.23
No. They are described as separate research-information products.
They share one Tirzepatide compound entity and largely the same research and regulatory source layer. One canonical page reduces near-duplicate content while preserving linkable strength sections.
No. Dosing and indication information belongs to the specific authorized medicine and is not provided as guidance for MedCore.
No. The MedCore site does not provide direct online checkout.

Authoritative Sources

The page uses standardized chemical identity and named regulator records for authorized tirzepatide medicines. Last reviewed 2 September 2026.

  1. 1
    PubChem: Tirzepatide, CID 156588324

    Compound identity, molecular formula, molecular weight and classification.

    Open PubChem source ↗
  2. 2
    European Medicines Agency: Mounjaro

    EU product-specific regulatory information identifying tirzepatide as the active substance.

    Open EMA source ↗
  3. 3
    U.S. FDA: FDA Approves New Medication for Chronic Weight Management

    FDA announcement regarding the specific approved tirzepatide medicine Zepbound and prior Mounjaro approval context.

    Open FDA source ↗
MEDCORE PEPTIDES

One Tirzepatide entity. Two MedCore strengths. Clear regulatory boundaries.

Review the quality framework or contact MedCore for product-specific documentation.

Quality & Documentation →Contact MedCore →
Research-use information: This page does not provide medical advice, dosing instructions or treatment recommendations, and does not represent MedCore Tirzepatide as Mounjaro, Zepbound or an authorized equivalent.
\n
Review the evidence contextUse the MedCore methodology and disclaimer when interpreting product research and documentation.
\n
\n\n